
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos is poised for growth with their innovative technologies and expanding product portfolio, potentially gaining market share in the treatment of various eye conditions. With strong revenue growth and profitability expected, the stock could continue to increase in value. While risks such as competition and reimbursement changes exist, the potential for upside from product launches and pipeline successes can offset these risks.
Bears say
Glaukos is facing risks such as increased competition in the MIGS market, potential difficulties with reimbursements, and slower adoption of their pipeline products. Their proposed LCDs for iDose may provide some relief, but overall their impact is expected to be limited. While the company has seen positive financial results with growing revenue and improved margins, there is still a potential downside from lower-than-expected market growth and slower product launches. Despite a strong track record and a robust pipeline, these risks contribute to a negative outlook on Glaukos's stock as its future performance could be impacted.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares